Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow
Examination of the Effect of Aqueous Suppressant Versus Aqueous Outflow Enhancing Glaucoma Medications on Ocular Perfusion Pressure and Blood Flow: A Mechanistic Study
調査の概要
状態
条件
詳細な説明
The purpose of this study will be to compare the aqueous production suppressant to aqueous outflow drugs in terms of the response to known vascular parameters. Specifically; systemic perfusion pressure, retrobulbar blood flow and retinal microcirculation.
A comparison of perfusion pressure, retinal microcirculation utilizing Heidelberg Retinal Flowmetry and retrobulbar circulation utilizing color Doppler ultrasound imaging
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Department of Ophthalmology Indiana University School of Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
Patients will meet all of the following inclusion criteria to enter the study:
- Age: 30 years or older.
Diagnosis: confirmed open-angle glaucoma in at least one eye:
- glaucomatous visual field loss on Humphrey 24-2 or 10-2 perimetry
- glaucomatous optic disc cupping
- agreement between two baseline exams for reliability
- Best corrected visual acuity at least 20/60 in at least one eye.
- Prior Humphrey visual fields demonstrate acceptable reliability standards (see below).
Exclusion Criteria:
- Extensive Humphrey visual field damage consisting of either a mean deviation (MD) < -15 decibels or a clinically determined threat to fixation in both hemifields.
- Evidence of exfoliation or pigment dispersion.
- History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy.
- History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis).
- History or signs of intraocular trauma.
- Severe or potentially progressive retinal disease such as retinal degeneration, diabetic retinopathy, and retinal detachment.
- Any abnormality preventing reliable applanation tonometry.
- Current use of any ophthalmic or systemic steroid which may interfere with this investigation.
- Cataract surgery within the past year.
- Resting pulse < 50 beats per minute.
- Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
aqueous suppressant
aqueous suppressant treated
|
|
aqueous outflow
aqueous outflow treated
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV)
時間枠:Baseline and 6 month visits
|
Baseline and 6 month visits
|
|
6-month Change in Phthalmic Artery (OA) End Diastolic Velocity (EDV)
時間枠:Baseline and 6 month visits
|
Baseline and 6 month visits
|
|
6-month Change in Phthalmic Artery (OA) Vascular Resistance (RI)
時間枠:Baseline and 6 month visits
|
Baseline and 6 month visits
|
|
6-month Change in Central Retinal Artery (CRA) Peak Systolic Velocity (PSV)
時間枠:Baseline and 6 month visits
|
Baseline and 6 month visits
|
|
6-month Change in Central Retinal Artery (CRA) End Diastolic Velocity (EDV)
時間枠:Baseline and 6 month visits
|
Baseline and 6 month visits
|
|
6-month Change in Central Retinal Artery (CRA) Vascular Resistance (RI)
時間枠:Baseline and 6 month visits
|
Baseline and 6 month visits
|
|
6-month Change in Ocular Perfusion Pressures (OPP)
時間枠:Baseline and 6 month visits
|
Baseline and 6 month visits
|
|
2-year Change in OA PSV
時間枠:Baseline and 24 month visits
|
Baseline and 24 month visits
|
|
2-year Change in OA EDV
時間枠:Baseline and 24 month visits
|
Baseline and 24 month visits
|
|
2-year Change in OA RI
時間枠:Baseline and 24 month visits
|
Baseline and 24 month visits
|
|
2-year Change in CRA PSV
時間枠:Baseline and 24 month visits
|
Baseline and 24 month visits
|
|
2-year Change in CRA EDV
時間枠:Baseline and 24 month visits
|
Baseline and 24 month visits
|
|
2-year Change in CRA RI
時間枠:Baseline and 24 month visits
|
Baseline and 24 month visits
|
|
2-year Change in OPP
時間枠:Baseline and 24 month visits
|
Baseline and 24 month visits
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Alon Harris, PhD、Indiana University School of Medicine
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。